Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DAUNOXOME vs VYXEOS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Daunorubicin intercalates between DNA base pairs, inhibiting topoisomerase II activity and preventing DNA replication and transcription. Liposomal encapsulation (Dauno Xome) alters distribution, reducing cardiotoxicity and enhancing tumor delivery.
Daunorubicin and cytarabine are both antineoplastic agents. Daunorubicin intercalates with DNA, inhibits topoisomerase II, and generates free radicals leading to DNA damage and cell death. Cytarabine is a nucleoside analog that inhibits DNA polymerase by competing with cytidine triphosphate, incorporating into DNA and RNA, and causing chain termination.
Treatment of advanced HIV-associated Kaposi sarcoma as first-line therapy,Acute myeloid leukemia (off-label),Acute lymphoblastic leukemia (off-label)
FDA: Treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients aged 1 year and older.
60-80 mg/m² intravenously over 1 hour every 2-4 weeks.
Each unit contains 44 mg daunorubicin and 100 mg cytarabine. Adults: 1 unit/m² IV over 90 minutes on days 1, 3, and 5 for induction; up to 2 cycles. For consolidation: 1 unit/m² IV over 90 minutes on days 1 and 3; up to 2 cycles.
Terminal elimination half-life is approximately 30-40 hours (range 20-48 h); prolonged compared to conventional doxorubicin due to liposomal encapsulation, allowing extended drug exposure.
Daunorubicin: terminal half-life approximately 56 h; cytarabine: terminal half-life approximately 31 h. The prolonged half-lives reflect sustained release from liposomes, allowing continuous exposure.
Primarily hepatically metabolized via reduction to daunorubicinol by cytoplasmic reductases, and additionally by aldo-keto reductases and NADPH-dependent enzymes. Excretion: biliary and renal.
Daunorubicin is metabolized via aldo-keto reductases to daunorubicinol, which is active. Cytarabine is primarily metabolized by cytidine deaminase to inactive uracil arabinoside (ara-U).
Primarily biliary/fecal (40-50% as unchanged drug and metabolites); renal excretion accounts for approximately 5-15% as unchanged drug and metabolites over 5 days.
Primarily hepatobiliary excretion; 70-80% of dose recovered in feces as metabolites, less than 10% in urine as unchanged liposomal daunorubicin and cytarabine.
Approximately 90-95% bound, primarily to plasma proteins (albumin); minimal displacement interactions reported.
Daunorubicin: approximately 60-70% bound to albumin and tissue proteins; cytarabine: approximately 15% bound to albumin.
Vd is approximately 2-3 L/kg, indicating extensive tissue distribution; liposomal formulation concentrates in RES organs (liver, spleen) and tumors with leaky vasculature.
Daunorubicin: Vd approximately 0.5-1 L/kg, indicating extensive tissue distribution; cytarabine: Vd approximately 0.3-0.5 L/kg, distributed mainly in total body water.
Only administered intravenously; oral bioavailability is negligible (<5%) due to extensive first-pass metabolism and instability in GI tract.
Not applicable (IV only); oral bioavailability not established for liposomal formulation.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) and consider dose reduction.
Contraindicated in severe renal impairment (Cr Cl < 30 m L/min). For Cr Cl 30-60 m L/min: reduce dose by 25%. Monitor renal function.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh C). For Child-Pugh B: reduce dose by 50%. For Child-Pugh A: no adjustment needed.
60-80 mg/m² intravenously over 1 hour every 2-4 weeks; safety and efficacy not established in children under 2 years.
Safety and efficacy not established. No standard pediatric dosing. Use only in clinical trials.
No specific dose adjustment; monitor for increased toxicity due to age-related organ dysfunction.
No specific dose adjustment based on age alone. Monitor renal and hepatic function; consider dose reduction in frail elderly patients due to increased toxicity risk.
Dauno Xome should be administered under the supervision of a physician experienced in cancer chemotherapy. Severe myelosuppression occurs. Cardiac toxicity, including potentially irreversible cardiomyopathy, may occur, especially with cumulative doses >600 mg/m². Extravasation can cause severe tissue necrosis.
WARNING: DAUNORUBICIN IS A CARDIOTOXIC AGENT. DAUNORUBICIN CAN CAUSE MYELOSUPPRESSION AND SEVERE BLEEDING. VYXEOS IS A LIPOSOMAL FORMULATION; DO NOT SUBSTITUTE FOR OTHER DAUNORUBICIN OR CYTARABINE PRODUCTS.
Monitor cardiac function (LVEF) regularly; cumulative dose limit 600 mg/m². Monitor blood counts for myelosuppression. Infusion reactions (hypotension, dyspnea) may occur. Not interchangeable with conventional daunorubicin.
Cardiotoxicity: Left ventricular dysfunction, especially with cumulative doses; monitor cardiac function.,Myelosuppression: Severe, can lead to fatal infections or bleeding.,Hemorrhage: Fatal hemorrhages reported.,Tumor lysis syndrome: Risk due to rapid lysis.,Hepatotoxicity: Elevations in bilirubin and transaminases.,Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception.
Hypersensitivity to daunorubicin or any component of Dauno Xome. Severe hepatic impairment. Severe, pre-existing myelosuppression. Pregnancy (category D).
Hypersensitivity to daunorubicin, cytarabine, or any component of the formulation.,History of serious hypersensitivity reactions to any conventional daunorubicin or cytarabine product.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition altering drug metabolism. No other significant food interactions. Maintain adequate hydration to prevent tumor lysis syndrome.
No specific food interactions reported. Avoid grapefruit and grapefruit juice due to potential CYP3A4 interaction with other components, although data are limited. Maintain adequate hydration to prevent tumor lysis syndrome.
Daunorubicin (Dauno Xome) is teratogenic in animal studies. First trimester: Avoid; major congenital malformations (cardiac, skeletal) reported. Second/third trimester: Use only if benefit outweighs risk; risk of fetal growth restriction, preterm birth, and neonatal myelosuppression. Fetal toxicity is dose-dependent.
VYXEOS (daunorubicin and cytarabine liposome) is contraindicated in pregnancy. It is embryotoxic and fetotoxic in animals. First trimester: high risk of major malformations (neural tube, cardiac). Second/third trimester: risk of fetal growth restriction, preterm birth, and neonatal myelosuppression. Use effective contraception.
Contraindicated during breastfeeding. Daunorubicin is excreted into human milk; M/P ratio not available. Potential for severe adverse reactions (immunosuppression, neutropenia, carcinogenesis) in the nursing infant. Advise to discontinue breastfeeding for at least 7-10 days after last dose.
Not recommended. It is unknown if excreted into human milk. M/P ratio not available. Advise to discontinue breastfeeding during treatment and for at least 1 month after last dose due to potential for serious adverse reactions in breastfed infants.
No established dosing guidelines. Use lowest effective dose with standard body surface area calculations. Increased volume of distribution in pregnancy may require dose increase, but lack of safety data. Monitor for enhanced toxicity; consider dose reduction if severe myelosuppression or cardiotoxicity occurs.
No established dosing guidelines in pregnancy. Avoid use; if therapy is necessary, dose adjustments based on pharmacokinetic changes are not defined. Use only if potential benefit justifies risk to fetus.
Dauno Xome (liposomal daunorubicin) has reduced cardiotoxicity compared to conventional daunorubicin due to preferential uptake by reticuloendothelial system. Cumulative lifetime dose limit is 600-800 mg/m² in adults (higher than conventional daunorubicin). Monitor for infusion reactions (flushing, dyspnea) especially during first dose. Myelosuppression is dose-limiting. Premedicate with antiemetics. Not interchangeable with conventional daunorubicin on mg/m² basis.
VYXEOS is a liposomal encapsulation of daunorubicin and cytarabine in a fixed 1:5 molar ratio. It is indicated for adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Do not substitute with other daunorubicin/cytarabine products due to different pharmacokinetics. Monitor for cardiotoxicity (echocardiogram prior to each cycle), myelosuppression, and hepatotoxicity. Premedicate for infusion reactions. Administer as a 90-minute IV infusion on days 1, 3, and 5; no dose adjustment for mild-moderate renal or hepatic impairment but avoid in severe impairment.
This medication may cause temporary hair loss, nausea, vomiting, and mouth sores.,Report any signs of infection (fever, chills) or unusual bleeding/bruising immediately.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception during therapy and for 6 months after last dose.,Do not receive live vaccines during treatment.
VYXEOS is a combination chemotherapy used for certain types of acute myeloid leukemia.,It is given as an intravenous infusion over 90 minutes on days 1, 3, and 5 of each treatment cycle.,Common side effects include fever, infection, nausea, vomiting, diarrhea, constipation, mouth sores, fatigue, and bleeding or bruising.,You will have regular blood tests to monitor blood counts, heart function, and liver function.,Report any signs of infection (fever, chills), bleeding (unusual bruising, black stools), shortness of breath, or chest pain immediately.,Avoid pregnancy and breastfeeding while on this medication.,Do not take any other medications, including over-the-counter drugs or supplements, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DAUNOXOME vs VYXEOS, answered by our medical review team.
DAUNOXOME is a Anthracycline Antineoplastic that works by Daunorubicin intercalates between DNA base pairs, inhibiting topoisomerase II activity and preventing DNA replication and transcription. Liposomal encapsulation (Dauno Xome) alters distribution, reducing cardiotoxicity and enhancing tumor delivery.. VYXEOS is a Liposomal Antineoplastic Combination that works by Daunorubicin and cytarabine are both antineoplastic agents. Daunorubicin intercalates with DNA, inhibits topoisomerase II, and generates free radicals leading to DNA damage and cell death. Cytarabine is a nucleoside analog that inhibits DNA polymerase by competing with cytidine triphosphate, incorporating into DNA and RNA, and causing chain termination.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DAUNOXOME and VYXEOS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DAUNOXOME is: 60-80 mg/m² intravenously over 1 hour every 2-4 weeks.. The standard adult dose of VYXEOS is: Each unit contains 44 mg daunorubicin and 100 mg cytarabine. Adults: 1 unit/m² IV over 90 minutes on days 1, 3, and 5 for induction; up to 2 cycles. For consolidation: 1 unit/m² IV over 90 minutes on days 1 and 3; up to 2 cycles.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DAUNOXOME and VYXEOS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DAUNOXOME is classified as Category C. Daunorubicin (DaunoXome) is teratogenic in animal studies. First trimester: Avoid; major congenital malformations (cardiac, skeletal) reported. Second/third trimester: Use only if . VYXEOS is classified as Category C. VYXEOS (daunorubicin and cytarabine liposome) is contraindicated in pregnancy. It is embryotoxic and fetotoxic in animals. First trimester: high risk of major malformations (neural. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.